Extended follow-up with the Bruton’s tyrosine kinase inhibitor ibrutinib in previously treated Waldenström’s macroglobulinemia Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Fluorodeoxyglucose F18
  • Hodgkin Disease
  • Lymphoma, Large B-Cell, Diffuse
  • Radiopharmaceuticals

publication date

  • October 27, 2016

Research

keywords

  • Article

Identity

Digital Object Identifier (DOI)

  • 10.1080/10428194.2016.1247957

Additional Document Info

start page

  • 1

end page

  • 4